- Home
- BANX vs FATE Comparison
BANX vs FATE Comparison
Compare BANX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANX | FATE |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.0M | 139.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BANX | FATE |
|---|---|---|
| Price | $21.00 | $1.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 23.4K | ★ 1.8M |
| Earning Date | 06-17-2025 | 03-04-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $29,467,794.00 | $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.88 | ★ N/A |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $17.99 | $0.66 |
| 52 Week High | $21.67 | $1.94 |
Technical Indicators
Market Signals| Indicator | BANX | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 50.22 |
| Support Level | $20.80 | $1.11 |
| Resistance Level | $21.56 | $1.26 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 32.64 | 39.66 |
Price Performance
Historical ComparisonAbout BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.